

Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026

<https://marketpublishers.com/r/G653E7D7AD0FEN.html>

Date: November 2021

Pages: 222

Price: US\$ 3,000.00 (Single User License)

ID: G653E7D7AD0FEN

Abstracts

Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.

Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026 Report Analysis and Data Highlights:

Research Methodology

Global & Regional Market Analysis

Global BCMA Targeted Drugs Market Opportunity Assessment: > USD 4 Billion

Market and Drug Sales Insight 2020 Till 2026

Approved Drug In Market: 2 Drugs

Approved BCMA Targeted Drugs Patent, Price and Sales insight 2020 Till 2026

Future Market Assessment By Indication Till 2026

Ongoing Clinical Trials Assessment by Status, Phase & Region

Key Market Dynamics

Competitor Landscape

Over a period of time, the cancer research has deviated for conventional approach and is directed towards the development of novel drugs that selectively targets the oncogenes, thereby reducing the adverse side effects. Genomic analysis have shown that B-cell maturation antigen or CD269 is restrictively expressed in both normal as well as malignant cells at high levels, thus making it an ideal target antigen for development of novel multiple myeloma therapies. BCMA is a member of tumor necrosis factor family and has critical role in the regulating B-cell proliferation and survival. The interaction of BCMA with its ligand has also shown to promote the progression of cancer. Further, studies have also demonstrated that BCMA is central to the survival of multiple myeloma cells. Therefore, researchers have adopted several approaches to target this antigen as an alternative for the management of multiple myeloma.

Currently, multiple innovative BCMA-targeted treatment modalities, including antibody-drug conjugate (ADC), CAR-T cells, and bispecific T cell engager (BiTE), are under active clinical development. However, two BCMA targeted drug modalities have also entered the market. Belantamab mafodotin (Blenrep) developed by GlaxoSmithkline was the first BCMA targeted drug approved for patients with relapsed or refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent. It is an antibody drug conjugate which consists of humanized anti-BCMA IgG1 monoclonal antibody conjugated to monomethyl auristatin F (MMAF, mafodotin) via a non-cleavable maleimidocaproyl (MC) linker.

In April 2021, Abecma developed by Bristol Meyer Squibb has also gain entry into market for the management of multiple myeloma. Abecma is BCMA directed genetically modified autologous chimeric antigen receptor (CAR) T-cell therapy which is approved for the same indication. The entry of Abecma in the market is expected to have a negative impact on the growth of Blenrep sales which is mainly due to its novel mechanism of action, better survival rates, and ability to overcome the limitations of Blenrep. As per our analysis, Abecma will dominate the market during the forecast period. Apart from multiple myeloma, researchers are also evaluating the role of these drugs in other therapeutic conditions including AL Amyloidosis, and various subtypes of lymphoma which will further drive the growth of market. In addition, several ongoing clinical trials are also evaluating the use of Abecma in combination with other modalities including pembrolizumab, dexamethasone, and other chemotherapeutic agents which aim to enhance the efficacy of the treatment, which will boost this segment during forecast period.

The active research and development in this sector will drive the growth of the market.

At present, several BCMA targeting drugs including ciltacabtagene autoleucel, Allo715, CTX-120, MCARH171, and others are present in clinical pipeline which are expected to gain approval during the forecast period. For instance, US FDA has recently granted priority review for ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor (CAR) T-cell therapy developed by Janssen. The rapid approval of these drugs during the forecast period will also drive the growth of market.

The global BCMA targeted drugs market is expected to witness high growth rates during the forecast period attributing mainly to the increase in prevalence of cancers and rates at which conventional therapies are failing. Moreover, key players in the market are strategically partnering and collaborating to expand the product portfolio and geographical presence of the company. Amid region, North America dominated the global market which is mainly credited to the growing number of research and development activities, presence of large pharmaceutical sector and high adoption rates of already approved therapies. Other regions such as Europe, Asia-Pacific are also expected to grow at high rates due to increase in prevalence of disorders and rising awareness among the population.

Contents

1. INTRODUCTION TO BCMA TARGETING THERAPY

- 1.1 Overview
- 1.2 History of BCMA Targeting Therapeutics

2. BCMA TARGETING THERAPEUTICS MECHANISM OF ACTION

3. BCMA AS IDEAL TARGET FOR HEMATOLOGICAL CANCER

4. GLOBAL BCMA TARGETING DRUGS MARKET ANALYSIS

- 4.1 Overview
- 4.2 Future Opportunity

5. GLOBAL BCMA TARGETING DRUGS MARKET OPPORTUNITY BY REGION

- 5.1 US
- 5.2 Europe
- 5.3 Japan
- 5.4 Rest of World

6. GLOBAL BCMA TARGETING DRUGS MARKET BY CANCER TYPE

- 6.1 Multiple Myeloma
- 6.2 Lymphoma
- 6.3 Leukemia

7. BLENREP (BELANTAMAB MAFODOTIN-BLMF) - FIRST APPROVED BCMA TARGETING THERAPY

- 7.1 Overview
- 7.2 Dosage & Price Analysis
- 7.3 Sales Analysis

8. ABECMA (IDECABTAGENE VICLEUCEL) - SECOND APPROVED BCMA TARGETING THERAPY

8.1 Overview

8.2 Dosage, Price & Sales Analysis

9. BCMA TARGETING DRUGS SALES FORECAST 2026

9.1 Blenrep

9.2 Abecma

10. BCMA TARGETING DRUGS CLINICAL TRIALS INSIGHT

10.1 By Phase

10.2 By Development Status

10.3 By Region

11. BCMA TARGETING DRUGS MARKET - ONGOING RESEARCH & DEVELOPMENT

11.1 Ciltacabtagene Autoleucel (JNJ-68284528)

11.2 Allo715

11.3 CTX120

11.4 C-CAR088

11.5 CT053

11.6 HPN217

11.7 Pacanalotamab (AMG 420/ BI 836909)

11.8 PHE

11.9 bb21217

11.10 SEA BCMA

12. GLOBAL BCMA TARGETED DRUGS CLINICAL TRIALS INSIGHT

12.1 Research

12.2 Preclinical

12.3 Clinical

12.4 Phase-0

12.5 Phase-I

12.6 Phase-I/II

12.7 Phase-II

12.8 Phase-II/III

12.9 Phase-III

12.10 Preregistration

13. APPROVED BCMA TARGETED DRUGS CLINICAL INSIGHT

13.1 Belantamab Mafodotin - GlaxoSmithKline

13.2 Idecabtagene Vicleucel - Bluebird Bio/Celgene Corporation

14. GLOBAL BCMA TARGETING DRUG MARKET DYNAMICS

14.1 Market Drivers

14.2 Market Challenges

15. GLOBAL BCMA TARGETING DRUG MARKET FUTURE OUTLOOK

16. COMPETITIVE LANDSCAPE

16.1 Allogene Therapeutics

16.2 AbbVie

16.3 Amgen

16.4 BioTherapeutics

16.5 Bluebird Bio

16.6 Bristol Mayer Squibb

16.7 Carsgen Therapeutics

16.8 Celgene

16.9 Cogent Bioscience

16.10 CRISPR Therapeutics

16.11 GlaxoSmithKline

16.12 Harpoon Therapeutics

16.13 Hrain Biotechnology

16.14 iCell Gene Therapeutics

16.15 Johnson & Johnson

16.16 Juno Therapeutics

16.17 Novartis

16.18 Poseida Therapeutics

16.19 Seagen

16.20 Seattle Genetics

List Of Figures

LIST OF FIGURES

Figure 1-1: Evolution of BCMA Targeting Therapeutics

Figure 2-1: BCMA Signaling Pathways

Figure 2-2: BCMA Targeting Therapeutics – Mechanism of Action

Figure 2-3: Blenrep - Mechanism of Action

Figure 2-4: Abecma - Mechanism of Action

Figure 3-1: Role of BCMA in Cell Cycle Signaling Pathway Regulation

Figure 3-2: Strategies For Targeting BCMA

Figure 3-3: Role of BCMA in Cancer

Figure 4-1: Global – Newly Diagnosed Leukemia Cases, 2020 - 2026

Figure 4-2: Global – Newly Diagnosed Hodgkin’s Lymphoma Cases, 2020 - 2026

Figure 4-3: Global – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026

Figure 4-4: Global – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026

Figure 4-5: Global – BCMA Targeting Therapy, Blood Cancer Therapeutics & Multiple Myeloma Therapeutics Market (US\$ Billion), 2020

Figure 4-6: Global – BCMA Targeting Therapy Market Opportunity (US\$ Million), 2020-2026

Figure 4-7: Global – Blood Cancer Drug Market Opportunity (US\$ Billion), 2020-2026

Figure 4-8: Global – Multiple Myeloma Drug Market Opportunity (US\$ Billion), 2020-2026

Figure 4-9: Global – BCMA Targeting Therapy Market by Product (%) 2026

Figure 5-1: US – Newly Diagnosed Leukemia Cases, 2020 - 2026

Figure 5-2: US – Newly Diagnosed Hodgkin’s Lymphoma Cases, 2020 - 2026

Figure 5-3: US – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026

Figure 5-4: US – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026

Figure 5-5: US – BCMA Targeting Therapy Market Opportunity (US\$ Million), 2020-2026

Figure 5-6: US – BCMA Targeting Therapy Market by Product (%), 2026

Figure 5-7: Europe – Newly Diagnosed Leukemia Cases, 2020 - 2026

Figure 5-8: Europe – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026

Figure 5-9: Europe – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026

Figure 5-10: Europe – BCMA Targeting Therapy Market Opportunity (US\$ Million), 2020-2026

Figure 5-11: Europe – BCMA Targeting Therapy Market by Product (%), 2026

Figure 5-12: Japan – Newly Diagnosed Leukemia Cases, 2020 - 2026

Figure 5-13: Japan – Newly Diagnosed Hodgkin’s Lymphoma Cases, 2020 - 2026

- Figure 5-14: Japan – Newly Diagnosed Non-Hodgkin’s Lymphoma Cases, 2020 - 2026
- Figure 5-15: Japan – Newly Diagnosed Multiple Myeloma Cases, 2020 - 2026
- Figure 5-16: Japan – BCMA Targeting Therapy Market Opportunity (US\$ Million), 2022-2026
- Figure 5-17: Japan – BCMA Targeting Therapy Market by Product (%), 2026
- Figure 5-18: ROW – BCMA Targeting Therapy Market Opportunity (US\$ Million), 2021 -2026
- Figure 5-19: ROW – BCMA Targeting Therapy Market by Product (%), 2026
- Figure 5-20: ROW – BCMA Targeting Therapy Market Share by Countries (%), 2026
- Figure 6-1: Global – Number of Multiple Myeloma Cases, 2021-2026
- Figure 6-2: Global – Multiple Myeloma Targeting BCMA Targeting Therapeutics Market Opportunity (US\$ Million), 2021 - 2026
- Figure 6-3: Global – Number of NHL Cases, 2021-2026
- Figure 6-4: Global – Number of Hodgkin’s Lymphoma Cases, 2021-2026
- Figure 6-5: Global – BCMA Targeting Therapeutics Market Opportunity in Lymphoma (US\$ Million), 2025 & 2026
- Figure 6-6: Global – Number of Newly Diagnosed Leukemia Cases, 2021-2026
- Figure 6-7: Global – BCMA Targeting Therapeutics Market Opportunity in Leukemia (US\$ Million), 2025 & 2026
- Figure 7-1: US - Blenrep FDA Approval & Orphan Designation Year
- Figure 7-2: Europe - Blenrep EMA Approval & Orphan Designation Year
- Figure 7-3: US - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (US\$), November’2021
- Figure 7-4: Europe - Price for 100mg Supply & Price for Single Treatment Cycle using Blenrep (GBP), November’2021
- Figure 7-5: Blenrep – Initial & Reduced Dose (mg/kg/3 Week)
- Figure 7-6: Global - Blenrep Quarterly Sales Value (US\$/GBP Million), Q1 – Q3, 2021
- Figure 7-7: US - Blenrep Quarterly Sales Value (US\$/GBP Million), Q1 – Q3, 2021
- Figure 7-8: Europe - Blenrep Quarterly Sales Value (US\$/GBP Million), Q1 – Q3, 2021
- Figure 7-9: Global - Blenrep Sales Value by Region (US\$/GBP Million), H1 2021
- Figure 7-10: Global – Blenrep Half Yearly Sales Share by Region (%), H1 2021
- Figure 7-11: Global - Blenrep Quarterly Sales Value by Region (US\$/GBP Million), Q3, 2021
- Figure 7-12: Global – Blenrep Quarterly Yearly Sales Share by Region (%), Q3, 2021
- Figure 7-13: Global - Blenrep Quarterly Sales Value (US\$/GBP Million), Q3 & Q4, 2020
- Figure 7-14: US - Blenrep Quarter Sales Value (US\$/GBP Million), Q3 & Q4, 2020
- Figure 7-15: Europe - Blenrep Quarter Sales Value (US\$/GBP Million), Q3 & Q4, 2020
- Figure 7-16: Global - Blenrep Annual Sales Value by Region (US\$/GBP Million), 2020
- Figure 7-17: Global - Blenrep Sales Share in by Region (%), 2020

- Figure 8-1: US - Abecma FDA Approval & Orphan Designation Year
- Figure 8-2: Europe - Abecma EMA Approval & Orphan Designation Year
- Figure 8 3: Abecma – Minimum & Maximum Dosage of CAR Positive Viable T Cells (Million ells), November'2021
- Figure 8-4: Global - Abecma Quarterly Sales Value (US\$ Million), Q2 & Q3, 2021
- Figure 9-1: Global - Blenrep Sales Forecast (US\$ Million), 2021 - 2026
- Figure 9-2: US - Blenrep Sales Forecast (US\$ Million), 2021 - 2026
- Figure 9-3: Europe - Blenrep Sales Forecast (US\$ Million), 2022 - 2026
- Figure 9-4: Japan - Blenrep Sales Forecast (US\$ Million), 2022 - 2026
- Figure 9-5: ROW - Blenrep Sales Forecast (US\$ Million), 2022 - 2026
- Figure 9-6: Global - Abecma Sales Forecast (US\$ Million), 2021 - 2026
- Figure 9-7: US - Abecma Sales Forecast (US\$ Million), 2021 - 2026
- Figure 9-8: Europe - Abecma Sales Forecast (US\$ Million), 2022 - 2026
- Figure 9-9: Japan - Abecma Sales Forecast (US\$ Million), 2022 - 2026
- Figure 9-10: ROW - Abecma Sales Forecast (US\$ Million), 2022 - 2026
- Figure 10-1: Global – Number of BCMA Related Clinical Trials by Phase, November'2021
- Figure 10-2: Global – BCMA Related Clinical Trials by Phase, November'2021
- Figure 10-3: Global – Number of BCMA Related Clinical Trials by Development Status, November'2021
- Figure 10-4: Global – Number of BCMA Related Clinical Trials by Development Status (%), November'2021
- Figure 10-5: Global – Number of BCMA Related Clinical Trials by Region, November'2021
- Figure 11-1: Investigational BCMA Targeting Therapeutics
- Figure 11-2: CARTITUDE 1 Trial – Study Initiation & Completion Year
- Figure 11-3: CARTITUDE 2 Trial – Study Initiation & Completion Year
- Figure 11-4: CARTITUDE 4 Trial – Study Initiation & Completion Year
- Figure 11-5: ALLO715 Phase I Trial – Study Initiation & Completion Year
- Figure 11-6: CTX120 Phase I Trial – Study Initiation & Completion Year
- Figure 11-7: C CAR088 Phase I Trial – Study Initiation & Completion Year
- Figure 11-8: CT053 Phase II Trial – Study Initiation & Completion Year
- Figure 11-9: CT053 Phase I Trial – Study Initiation & Completion Year
- Figure 11-10: HPN217 Phase I Trial – Study Initiation & Completion Year
- Figure 11-11: AMG 420 Phase I Trial – Study Initiation & Completion Year
- Figure 11-12: PHE 885 Phase I Trial – Study Initiation & Completion Year
- Figure 11-13: bb21217 Phase I Trial – Study Initiation & Completion Year
- Figure 11-14: SEA BCMA Phase I Trial – Study Initiation & Completion Year
- Figure 12-1: Global – number of BCMA Targeted Drug in Clinical trials, 2021 -2026

Figure 14-1: Global BCMA Targeting Therapy Market Drivers

Figure 14-2: Challenges for Global BCMA Targeting Therapy Market

Figure 14-3: US – Annual Cost Comparison of BCMA Targeting Therapy with other Treatments (US\$), September'2021

I would like to order

Product name: Global B Cell Maturation Antigen (BCMA) Targeted Therapy Market & Clinical Trials Insight 2026

Product link: <https://marketpublishers.com/r/G653E7D7AD0FEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G653E7D7AD0FEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

